BAJAJ BROKING
In the, Gland Pe quarterly results, Gland Pharma showed an impressive 41 percent surge in revenue for the April-June quarter. The financial gurus interpret this increase as an early signal that the company’s core business is getting back on track.
However, there’s a bit of a twist. Despite the good news, some challenges persist. Sizeable expenses related to depreciation and finance, along with not-so-great operating margins, pulled down the company’s profits by 15.3 percent compared to the previous year, landing at Rs 194.1 crore for the quarter.
But wait, there’s more! As of 10:16 AM, the company’s shares were being traded on the NSE at Rs 1,611.05, marking a whopping 20 percent surge from the previous day’s closing price. Now that’s what you call a stock market roller-coaster!
The bullish momentum in shares of India’s healthcare companies gathered steam with the Nifty Pharma hitting an all-time high on Monday with a surge of 1.16%.
Disclaimer- Investments in the securities market are subject to market risk, read all related documents carefully before investing. The article is only for information purpose and is not a recommendation.Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. Corp. Office: Bajaj Broking., 1st Floor, Mantri IT Park, Tower B, Unit No 9, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O (Member ID: 6706) | NSE Cash/F&O (Member ID: 90177) | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN – 163403. Website: https://www.bajajfinservsecurities.in/
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading